The Pharma Marketers Guide to Medication Adherence
Improving brand adherence rates requires pharma marketers to have access to two growing bodies of knowledge. These are: 1) carefully evaluated evidence for what can improve brand revenue, and 2) informed forecasts of trends.
Improving brand adherence rates requires pharma marketers to have access to two growing bodies of knowledge. These are: 1) carefully evaluated evidence for what can improve brand revenue, and 2) informed forecasts of trends.
Patient Adherence and Access Summit
June 17–18, 2014
Philadelphia, Pennsylvania
RELATED
- Changing the DNA of Pharma Patient Adherence Programs
- Why Patient Adherence is a Policy Issue
- The First and Last Word on Medication Adherence: Keep Trying
MORE IN PATIENT ADHERENCE & ACCESS
How can this knowledge help? Many recent industry programs have achieved only a 1-3% increase in adherence, and ROIs of less than 3. To realize results of 20%+ and ROIs above 3/1, critical appraisal of the past and direction to probable futures are needed (several pharma companies have achieved 38%+ lifts in persistence with this new knowledge). This experience can provide the pharma marketer with a needed guide to planning and program implementation.
At this month’s Center for Business Intelligence (CBI) Patient Adherence and Support Summit (April 29-30), in Philadelphia, brand directors and marketers will have a unique opportunity to hear senior VP’s, consultants and academic researchers provide their perspectives on what we know and need to target in 2013.
The event will begin with a keynote panel speaking about the changing DNA of patient adherence programs. Presenters will be VP’s and Senior Directors from Eli Lilly, GSK, Sanofi, and Shire.
For the first time since the inception of CBI’s Strategic Patient Adherence (SPA) Awards, there will be a look back at where the winning programs are today. This panel will follow presentation of an Adherence Roadmap by Dr. William Shrank, a prolific adherence researcher.
Tuesday will include a unique opportunity to hear one of the world’s most cited industry researchers, Merck’s Dr. Colleen McHorney. Dr. McHorney will be reviewing the history of adherence research and how the paradigm has shifted.
For more information on this event, now in its 12th year, go to:
http://www.cbinet.com/conference/pc13116#.UVx-3KLvHE0
For more information on this article, you can reach Grant Corbett, Principal, Behavior Change Solutions, Inc. at grant.corbett@behavior-change-solutions.com.
See also: http://blog.pharmexec.com/2013/03/12/changing-the-dna-of-pharma-patient-adherence-programs/
Phase III Trials Show Povorcitinib Significantly Improves Hidradenitis Suppurativa Outcomes
March 19th 2025In the Phase III STOP-HS1 and STOP-HS2 trials, results show that patients treated with povorcitinib for hidradenitis suppurativa experienced a ≥50% reduction in the total abscess and inflammatory nodule count.
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
